Please login to the form below

Not currently logged in
Email:
Password:

Sanaria

This page shows the latest Sanaria news and features for those working in and with pharma, biotech and healthcare.

Dosing of GSK's malaria vaccine due to start in 2018

Dosing of GSK's malaria vaccine due to start in 2018

Another malaria vaccine developed by US biopharma company Sanaria – called PfSPZ – has been shown to offer improved protection rates, possibly as high as 80%, as well as a duration of action

Latest news

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    A malaria vaccine in development by US biopharma company Sanaria has demonstrated sustained protection against the parasite, according to the results of a clinical trial. ... Sanaria's vaccine - which has been developed alongside researches at the

  • GSK hoping to file malaria vaccine next year GSK hoping to file malaria vaccine next year

    In the summer, researcher at the US National Institutes of Health (NIH) reported encouraging early clinical of another candidate called PfSPZ - in development at small US biotech Sanaria - which provided complete

  • Malaria vaccine gives Malaria vaccine gives "unprecedented" results

    The results of the NIH-backed study have thrown the US biotech behind the vaccine - Rockville, Maryland-based Sanaria - into the spotlight, although chief executive Stephen Hoffman stressed the development work

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics